Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2014Journal of Crohn s and ColitisOpen Access

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

View Full Paper
Ask AI
Bookmark
Share

Authors

Silvio Danese
Silvio DaneseUniversità Cattolica del Sacro CuoreGFGionata FiorinoAzienda Ospedaliera San Camillo-ForlaniniPMPierre MichettiBee Research Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Danese et al. (2014) studied this question.

synapsesocial.com/papers/6a830ad9c4b5dbf8331f2940https://doi.org/10.1016/j.crohns.2014.06.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)2013 · 193 citations
  2. 2A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study2013 · 654 citations
  3. 3A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study2013 · 606 citations
  4. 4Evaluating equivalence and noninferiority trials2010 · 45 citations
  5. 5Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial2004 · 1,167 citations